The EEF2K Knockout Huh-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of Huh-7 human hepatocellular carcinoma cells with targeted disruption of the EEF2K gene. This loss-of-function model enables investigation of eukaryotic elongation factor 2 kinase in a heterogeneous knockout pool, avoiding clonal artifacts and supporting applications such as pooled functional screening and stress-response profiling.
The parental Huh-7 line is a well-differentiated, p53-mutated hepatocellular carcinoma line derived from a liver tumor of a 57-year-old Japanese male. It is widely used for liver cancer research, hepatitis C virus studies, and hepatocyte biology due to its retention of hepatocyte-specific features and tumorigenic properties.
EEF2K is a calcium/calmodulin-dependent kinase that phosphorylates elongation factor 2 (eEF2) at Thr56, inhibiting translational elongation and attenuating global protein synthesis. Its activity is stimulated by AMPK-mediated phosphorylation under energy stress and hypoxia, and suppressed by mTORC1/S6K and cAMP/PKA signaling. The kinase interacts with calmodulin and AMPK subunits, and is a central regulator linking nutrient status to translation control. Beyond translation, EEF2K promotes autophagy induction and participates in the unfolded protein response, facilitating cellular survival under metabolic adversity. Dysregulated EEF2K activity supports cancer cell adaptation and resistance to nutrient deprivation.
In the Huh-7 hepatocellular carcinoma context, EEF2K knockout disrupts a key survival pathway, sensitizing cells to energy depletion and nutrient stress. This model is critical for dissecting EEF2K??s role in liver cancer metabolism, where the kinase often contributes to tumorigenesis through translational reprogramming and autophagy. The polyclonal nature of the knockout pool mitigates clonal selection biases, ensuring that phenotypes are attributable to loss of EEF2K function.
Researchers can employ this model to study EEF2K-dependent proliferation via colony formation and growth assays, monitor translational effects using phospho-eEF2 (Thr56) western blotting and polysome profiling, and assess autophagic flux and metabolic responses using Seahorse analysis. It is also valuable for drug sensitivity testing and evaluating EEF2K as a therapeutic target in HCC. For further technical details, please contact Ascent Research.
